LAUSR

1. Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumabcombination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10): 1139-1149. 2. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328e346. 3. Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713-1722. 4. Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422-431. 5. Paiva B, Gutiérrez NC, Rosiñol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3): 687-691. 6. Schinke C, Hoering A, Wang H, et al. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017; 102(8):e313-e316. 7. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. 8. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large metaanalysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23): 5988-5999. 9. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28-35. 10. Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900-2910. 11. Paiva B, Corchete LA, Vidriales MB, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15): 1896-1906. 12. Goicoechea I, Puig N, Cedena MT, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma. Blood. 2021;137(1):49-60. 13. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735-1744. 14. Weinhold N, Heuck CJ, Rosenthal A, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30(2):423-430. 15. Mohan M, Yarlagadda NK, Atwal D, et al. Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma. J Clin Oncol. 2020;38(15 suppl):8514. 16. Mohan M, Kendrick S, Pandey Y, et al. Late relapsing multiple myeloma ≥ 10 years after treatment on total therapy protocols are associated with good outcome. Blood. 2020;136(suppl 1):11-12. 17. Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, et al. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020;61(12):2868-2875. 18. Majithia N, Vincent Rajkumar S, Lacy MQ, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015;90(11):981-985. 19. Wudhikarn K, Mailankody S, Smith EL. Future of CAR T cells in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2020;2020 (1):272-279.